Subject Index

A
A protease inhibitor of CD13, S31
Adjuvant chemotherapy, S31, S32
Adjuvant immunotherapy, S31
Advanced non small cell lung cancer, S47
Afatinib, S41
Akt, S12
ALK gene, S7
anaplastic lymphoma kinase (ALK) S9, S33
Awareness program, S18
B
BCL3, S23
Benign lesions, S9
Benzo (a) pyrene, S13
Beta-glucan, S40
Bevacizumab, S29, S47, S49
Biomarkers, S24
Bone marker, S50
Bone metastases, S50
Bone morphogentic protein, S8
BRAF mutation, S30
Brain Metastases, S36, S46
Bronchoscopy, S27
C
Cabazitaxel, S28
Cabozantinib, S38
Cancer, S17
Cancer registries, S14
Cancer stem cell, S33
Cancer vaccine, S23
Cancer-related anemia, S48
CCRT, S35
CD133, S33
CD47, S30
Cell culture, S8
cell-free DNA, S9
Cetuximab, S40
Chemo resistant, S29
Chemoradiation, S33
Chemo-radiotherapy, S35, S36
Chemoresistance, S21
Chemotherapy, S42
Chemotherapy-induced anemia, S48
Chest X-ray, S17
Chromosome 7 high polysomy, S44
Cigarette smoking, S11
Circulating tumor cells, S19
Cisplatin, S9, S47
c-MET gene, S7
CO-1686, S38
Comorbidity, S43
Companion diagnostic, S26
Companion imaging agent, S23
Comparative effectiveness research, S31
Comprehensive Histologic Assessment, S7
Computed tomography S14, S27
Cost-effectiveness, S16
CT imaging, S27
CT-guided biopsy, S27
ctrl1, S22
Curcumin, S22
Customized therapy, S36
Cyclooxygenase 2 (COX-2), S11
Cyclophosphamide, S29
Cytolysin, S12

D
Darbepoetin alfa, S48
Death-associated protein kinase (DAPK), S24
Disease progression, S28
Dose adjustment, S31
DOX, S13
Drug screening, S21

E
Early detection, S15, S16
Early diagnosis, S15
Early stage disease, S15, S31
EBUS-TBNA, S25
EGFR inhibitor, S22
EGFR mutation, S9, S10, S16, S19, S27, S36, S37, S40, S44, S45
EGFR tyrosine kinase inhibitor, S19
EGFR-TKI, S9, S38, S44
Elderly, S35, S43
Endobronchial ultrasound, S26, S27
Endobronchial ultrasound guided transbronchial needle aspiration, S27
Epidemiology, S14
Epidermal growth factor receptor (EGFR), S10
Epigallocatechin gallate (EGCG), S47
ERCC1, S9
Erlotinib, S37, S41
Erythropoiesis-stimulating agent, S48
Estrogen receptor beta, S8
Etarfolatide (EC20), S26
Ethnicity, S21
Evaluation, S18
Exon 20 insertion, S40
Extensive-stage SCLC, S20
Extrapleural pneumonectomy, S50
EZH-2, S11

F
18F-FDG PET/CT, S25, S51
FHIT, S13
First-line chemotherapy, S43
Fluorescent in situ hybridization (FISH), S7, S38
Folate, S26
Folate Receptor, S22
Free-circulating DNA, S19
Gefitinib, S38, S42
γ-Fe2O3-NC, S13
Gemcitabine, S20, S46
Gene E, S24
Gene expression analysis, S10
Gene expression signatures, S32
Gene rearrangement, S9, S33
Gene therapy, S25
Genetic alterations, S7
Genome wide association study, S32
Genomic profile, S38
Germ cell tumor, S52
GLOBOCAN, S17
Hedgehog, S51
High hydrostatic pressure, S23
Histology, S8
Hsp90, S19, S23

I
Imaging, S52
Immunohistochemistry, S7, S9, S23, S33
Immunotherapy, S25, S39, S41
Incidence, S17
Induction treatment, S35
Inhibitor of apoptosis protein, S21
Intensity modulated radiation therapy (IMRT), S35, S49
Interleukin-2, S47
Intraperitoneal therapy, S40
International, S17
Intrapleural hyperthermic chemotherapy, S47
Intrapleural treatment, S51
Irreversible EGFR-TKI, S38

L
LA-NSCLC, S35
Lepidic growth, S7, S10
Local ablation techniques, S25
Local tumor control, S34
Locally advanced disease, S35, S36
Locally advanced non-small cell, S35
Long non codingRNA, S51
LUME Lung 1, S39
Lung adenocarcinoma, S32, S44
Lung biopsy, S27
Lung cancer recurrence, S27
Lung cancer screening, S14, S17
Lung cancer, S7, S12, S13, S15, S16, S17, S18, S24, S27, S32, S42
Lung flooding, S25
Lung screening, S15

**M**

Macrophage, S30
Maintenance chemotherapy, S46
Malignant mesothelioma, S50, S51
Malignant pleural dissemination, S47
Malignant pleural effusion, S47
Malignant pleural mesothelioma, S14, S51
Mediastinal invasion, S34
Mediastinal tumor, S52
Mesothelioma, S50, S51
MET, S19
Meta-analysis, S42
Metabolic profile, S13
microRNA (miRNA), S14, S16, S20, S22, S50
Microsatellite marker, S13
Mixed pathology tumour, S30
Molecular biomarkers, S30
Morphogenetics, S12
Morphology, S27
Mouse model, S13
mTOR pathway, S11
mTOR, S10
Mucin 1, S25
Multifocal lung adenocarcinoma, S7
Napsin A, S10

**N**

Neoadjuvant therapy, S36
New targeted therapies, S30
Nintedanib, S39, S41
Non-small cell lung cancer (NSCLC), S9, S11, S12, S14, S16, S18, S19, S20, S22, S23, S24, S25, S26, S12, S33, S34, S35, S36, S37, S38, S39, S40, S41, S42, S43, S44, S45, S46, S47, S48, S49, S50
Nuclear target, S13

**O**

Oligometastatic disease, S42, S49
Outcome prediction, S20
Outcomes, S27
Overall survival (OS), S29, S33

**P**

p53, S11, S13
Paclitaxel, S25, S29
Palliative radiotherapy, S45
Pathological stage I, S31
Pathology, S52
Patient selection, S23
PD-1, S18
PD-L1, S18
Pemetrexed, S19, S41, S45, S46
Phase III, S39
Plasma Biomarkers, S9, S25
Platinum resistance, S21
Polymorphisms, S16, S32
Population-based study, S15
Post-operative radiotherapy, S34
Post-operative, S36
Predictive biomarker, S12, S41
Predictive factor, S19
Predictor, S31
Previously treated, S47
Prognosis S10, S16, S32, S38
Prognostic factors, S52
Prognostic marker, S8
Prognostic signature, S50
Programmed death-1 ligand, S41
Programmed death-1 receptor, S39
Progression-free survival (PFS), S24
Prolonged low-dose infusion, S46
Proteasome, S23
PS2, S42
PTK7, S12
Pulmonary neuroendocrine tumors, S10

**Q**

Quality assurance, S26
Quality of life (QOL), S37
Quantitative real-time polymerase chain reaction (Q-RT-PCR), S16
Quiescence, S51

**R**

Radiation therapy, S21, S33, S35
Rash, S41
Rechallenge chemotherapy, S28
Recurrence, S8, S51
Response, S35
Response to TKIs, S40
RET, S38
Retrospective study, S34, S46
Risk, S17
RNA FISH, S51
rs8100239, S23

**S**

Safe practices, S18
Safety, S49
Sarcomatoid, S7
SBRT, S49
Sea anemone venoms, S12
Second-line chemotherapy S28, S29
Smac mimetics, S21
Small cell lung cancer (SCLC), S28, S29, S30
SNP, S23
Solitary fibrous tumor of the pleura, S52
Solitary nodule, S31
Somatic profiling, S19
South India, S18
Spore-forming bacillus S11
Squamous cell carcinoma, S16, S31, S40
Src, S22
Stage I lung adenocarcinoma, S10
Staging, S26
Standard dose, S46
Stereotactic radiotherapy, S15, S31
Study 20070782, S48
Subtyping lung adenocarcinomas, S12
Surgery, S34, S42
Survival, S8, S34, S35
Survival analysis, S14

**T**

T790M mutation, S38
Targeted therapy, S22
Telomerase activity, S24
Telomere length, S24
Temozolomide, S46
TGFR-beta signaling, S24
Therapeutic insufficiency, S29
Therapeutic regiments, S29
Therapeutic ultrasound, S25
Thymidylate synthase (TS), S41
Thyroid cancer, S27
TK1, S37, S40
Tobacco cessation, S18
Tobacco, S17
Topotecan, S28, S29
Transcriptomics, S20
Transporter, S21
Treatment, S43, S52
Tumor biology, S8
Tumor biomarker, S16
Tumor specific antibodies S11
Tumor volume, S37
Tyrrosine kinase inhibitor (TKI), S44

**V**

Vincristine, S29

**W**

Whole-brain radiation therapy, S49

**X**

Xiap, S22

**Y**

Young adults, S48